期刊文献+

西罗莫司-羟丙基-β-环糊精包合物的制备 被引量:2

Preparation of Sirolimus-hydroxypropyl-β-cyclodextrin Inclusion
原文传递
导出
摘要 目的:制备西罗莫司-羟丙基-β-环糊精(HP-β-CD)包合物,并考察HP-β-CD提高西罗莫司溶解度的效果。方法:以西罗莫司与HP-β-CD之比(mol:mol)、包合温度和包合时间为因素,包合率、收得率为指标,采用正交试验筛选西罗莫司-HP-β-CD包合物的制备工艺,并进行溶解度影响、X-射线衍射法结构验证。结果:最佳工艺为:西罗莫司与HP-β-CD之比为1:6(mol:mol)、包合温度为25℃、时间为6h;以此工艺制备3批包合物,平均包合率为25.4%(RSD=1.16%),平均收得率为86.5%(RSD=0.83%);随着HP-β-CD浓度增加,西罗莫司溶解度从1.18μg·mL-1增加到49.97μg·mL-1;包合物的晶体衍射峰形几乎与HP-β-CD完全一致。结论:HP-β-CD包合西罗莫司的工艺简单、易操作,能提高西罗莫司的溶解度。 OBJECTIVE:To prepare Sirolimus-hydroxypropyl-β-cyclodextrin(HP-β-CD)inclusion,and to investigate the improvement effect of HP-β-CD inclusion on the dissolution of sirolimus.METHODS:The preparation technology of Sirolimus-HPβ-CD inclusion was optimized by orthogonal test with ratio of sirolimus to HP-β-CD(mol:mol),inclusion temperature and inclusion time as factors using inclusion rate and yield rate as index.The validation test was conducted among dissolution and X-ray diffraction method structure.RESULTS:The optimal preparation technology was as follows:ratio of sirolimus to HP-β-CD of 1:6(mol:mol),inclusion temperature of 25 ℃,inclusion time of 6 h.Average inclusion rate of 3 batches of inclusion was 25.4%(RSD=1.16%)and average yield was 86.5%(RSD=0.83%).With the increase of HP-β-CD concentration,the dissolution of sirolimus increased from 1.18μg·mL-1 to 49.97μg·mL-1.The crystal diffraction profiles of inclusion were in line with those of HP-β-CD.CONCLUSION:The inclusion process of sirolimus with HP-β-CD is simple and easy to operate,and can improve the dissolution of sirolimus.
出处 《中国药房》 CAS CSCD 2012年第45期4275-4277,共3页 China Pharmacy
关键词 西罗莫司 羟丙基-Β-环糊精 包合物 正交试验 溶解度 Sirolimus Hydroxypropyl-β-cyclodextrin Inclusion Orthogonal design Dissolution
  • 相关文献

参考文献5

二级参考文献23

  • 1杜平中.两种新型大环内酯类免疫抑制剂[J].中国医药工业杂志,1995,26(7):330-333. 被引量:5
  • 2吴洪涛,刘任.新型免疫抑制剂FK506在器官移植中的应用进展[J].国外医学(泌尿系统分册),1996,16(1):28-30. 被引量:4
  • 3何媛,王四旺,吴红.桉油β-环糊精包合物的制备与鉴定[J].中国药房,2006,17(4):255-258. 被引量:20
  • 4Levin ED, Damaj MI, Glassco W, et al .Bridged nicotine, isonicotine, and norisonicotine effects on working memory performance of rats in the radial - arm maze [J ] .Drug Dew Res, 1999,46(2):107.
  • 5Baker RW, Santus G, Fridman SV. Method and therapeutic system for smoking cessation[J]. Drug Dev Ind Pharm ,2002,28(5) :721.
  • 6White HK, Levin ED. Four week nicotine skin patch treatment effects on cognitive performance in Alzheimer' s diseases [J] . Psychopharmacology, 1999,143(2) : 158.
  • 7REN J Q.Practical Handbook of Drugs(实用药物手册)[M].2nd Ed.Jinan:Shandong Science & Technology Press,2000:693-694.
  • 8LI R.Pharmacology(药理学)[M].4th Ed.Beijing:People' s Medical Publishing House,2002:196.
  • 9USP.26th Ed[S].2003:1526.
  • 10HIGUCHI T,CONNORS K.Phase-solubility techniques[J].Adv Anal Chem Instrum,1965,4:117-212.

共引文献25

同被引文献41

  • 1崔福德.药剂学[M].5版.北京:人民卫生出版社,2005:202.
  • 2中国药典.二部[S].2010:附录196.
  • 3Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of canner with rapamycin derivatives [J]. Ann Oncol, 2005, 16 (4):525- 537.
  • 4Spilman P, Podlutskaya N, Hart MJ,et al. Inhibition of mTOR by rapamycin abblishes cognitive deficits and reduces amyloid-beta levels in amouse model of Alzheimer' s disease [ J ]. PLoS One, 2010, 5 (4) : e9979.
  • 5Emami S, Valizadeh H, Islambulchilar Z, et al. Development and Physicochemical Characterization of Sirolimus Solid Dispersions Prepared by Solvent Evaporation Method[ J], Adv Pharm Bull, 2014, 4 (4) : 369-374.
  • 6Park SM, Kim MS, Park SJ, et al. Novel temperature-triggered liposome with high stability: Formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU) [ J ]. J Control Release, 2013,170(3) :373-379.
  • 7Fu J, Wang D, Wang T, et al. High Entrapment Efficiency of Chitosan/Polylactic Acid/Tripolyphotspate Nanosized Microcapsules for Rapamycin by an Emulsion-Evaporation Approach [ J ]. J Biomed Nanotechnol, 2010, 6(6): 725-728.
  • 8Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability[ J]. Int J Pharm, 2010, 394( 1-2 ) : 179185.
  • 9Zhang Z, Bu H, Gao Z, et al. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats[J]. Int J Pharm, 2010, 394(1-2): 147-153.
  • 10Kim MS, Kim JS, Park H J, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process [ J ]. Int J Nanomedicine, 2011 ( 6 ) : 29973009.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部